COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,903 Articles (22,568 medRxiv, 8,335 bioRxiv)

Most recent first Previous |  Page 2005: Articles 20041-20050  | Next

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode
Pradenas, E., Trinite, B., Urrea, V., Marfil, S., Avila-Nieto, C., Rodriguez de la Concepcion, M. L., Tarres-Freixas, F., Perez-Yanes, S., Rovirosa, C., Ainsua-Enrich, E., Rodon, J., Vergara-Alert, J., Sagales, J., Guallar, V., Valencia, A., Izquierdo-Useros, N., Paredes, R., Mateu, L., Chamorro, A., Massanella, M., Carrillo, J., Clotet, B., Blanco, J.
10.1101/2020.11.22.389056 — Posted: 2020-11-23
A Synthetic Defective Interfering SARS-CoV-2
Yao, S., Narayanan, A., Majowicz, S., Jose, J., Archetti, M.
10.1101/2020.11.22.393587 — Posted: 2020-11-23
The multidisciplinary nature of COVID-19 research
Arencibia-Jorge, R., Garcia-Garcia, L., Galban-Rodriguez, E., Carrillo-Calvet, H.
10.1101/2020.11.23.394312 — Posted: 2020-11-23
N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation
Zhou, W., Xu, C., Wang, P., Luo, M., Xu, Z., Cheng, R., Jin, X., Guo, Y., Xue, G., Juan, L., Nie, H., Jiang, Q.
10.1101/2020.11.21.392407 — Posted: 2020-11-23
A repurposed, blood gene signature is associated with poor outcomes in SARS-CoV-2
Juan-Guardela, B. M., Sun, J., Zhang, T., Xu, B., Michaud, G., Herazo-Maya, J. D.
10.1101/2020.11.21.392670 — Posted: 2020-11-23
Interactions of anti-COVID-19 drug candidates with multispecific ABC and OATP drug transporters
Telbisz, A., Ambrus, C., Mozner, O., Szabo, E., Varady, G., Bakos, E., Sarkadi, B., Ozvegy-Laczka, C.
10.1101/2020.11.21.392555 — Posted: 2020-11-23
Sensitivity Analysis on Predictive Capability of SIRD Model for Coronavirus Disease (COVID-19)
Sedaghat, A., Alkhatib, F., Oloomi, S. A. A., Ashtian Malayer, M., MOSAVI, A.
10.1101/2020.11.21.20236083 — Posted: 2020-11-23
Covid-19 pandemic lessons: Uncritical communication of test results can induce more harm than benefit and raises questions on standardized quality criteria for communication and liability
Porzsolt, F., Pfuhl, G., Kaplan, R. M., Eisemann, M.
10.1101/2020.11.20.20235424 — Posted: 2020-11-23
Catching a resurgence: Increase in SARS-CoV-2 viral RNA identified in wastewater 48 hours before COVID-19 clinical tests and 96 hours before hospitalizations
D'Aoust, P. M., Graber, T. E., Mercier, E., Montpetit, D., Alexandrov, I., Neault, N., Baig, A. T., Mayne, J., Zhang, X., Alain, T., Servos, M. R., Srikanthan, N., MacKenzie, M., Figeys, D., Manuel, D., Juni, P., MacKenzie, A. E., Delatolla, R.
10.1101/2020.11.22.20236554 — Posted: 2020-11-23
SARS-CoV-2 Reinfection in Patients Negative for Immunoglobulin G Following Recovery from COVID-19
Ali, A. M., Ali, K. M., Fatah, M. H., Towfeeq, H. M., Rostam, H. M.
10.1101/2020.11.20.20234385 — Posted: 2020-11-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).